Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo

Nutrition and Cancer

Volumn 64, Issue 4, 2012, Pages 599-606

  Sun, Fang ^a   Zheng, Xiang Yi ^b   Ye, Jia ^a   Wu, Ting Ting ^a   Wang, Jian Li ^a   Chen, Weilin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; GELATINASE B; MYRICETIN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CDC2 PROTEIN KINASE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; DOWN-REGULATION; FEMALE; FLAVONOIDS; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; URINARY BLADDER NEOPLASMS;

EID: 84861429437     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2012.665564     Document Type: Article

References (26)

1. Whelan P: Survival from bladder cancer in England and Wales up to 2001. Br J Cancer 99(Suppl 1), S90-S92, 2008.
2. Jemal A, Siegel R, and Ward E: Cancer statistics, 2009. CA Cancer J Clin 59, 225-249, 2009.
3. Mitra AP and Cote RJ: Molecular screening for bladder cancer: progress and potential. Nat Rev Uro 7, 11-20, 2010.
4. Kakehi Y, Hirao Y, and Kim WJ: Bladder Cancer Working Group report. Jpn J Clin Oncol 40(Suppl 1), i57-i64, 2010.
5. Voskresensky ON and Levitsky AP: QSAR aspects of flavonoids as a plentiful source of new drugs. Curr Med Chem 14, 1367-1383, 2002. (Pubitemid 34752587)
6. Zhang K, Ma Z, and Wang J: Myricetin attenuated MPP(+)-induced cytotoxicity by antioxidation and inhibition of MKK4 and JNK activation in MES23.5 cells. Neuropharmacology 61, 329-335, 2011.
7. Wang SJ, Tong Y, and Lu S: Anti-inflammatory activity of myricetin isolated from Myrica rubra Sieb. et Zucc. leaves. Planta Med 76, 1492-1496, 2010.
8. Zhang Q, Zhao XH, and Wang ZJ: Flavones and flavonols exert cytotoxic effects on a human oesophageal adenoearcinonla cell line (0E33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol 46, 2042-2053, 2008.
9. Lu J, Papp LV, and Fang J: Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66, 4410-4418, 2006.
10. Chen D, Daniel KG, and Chen MS: Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 69, 1421-1432, 2005. (Pubitemid 40602442)
11. De Leo M, Braca A, and Sanogo R: Antiproliferative activity of Pteleopsis suberosa leaf extract and its flavonoid components in human prostate carcinoma cells. Planta Med 72, 604-610, 2006.
12. Jung SK, Lee KW, and Byun S: Myricetin suppresses UVB-induced skin cancer by targeting Fyn. Cancer Res 68, 6021-6029, 2008.
13. Ko CH, Shen SC, and Lee TJ: Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells. Mol Cancer Ther 4, 281-290, 2005. (Pubitemid 40340207)
14. Singh RP, Tyagi A, Sharma G, Mohan S, and Agarwal R: Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving downregulation of survivin. Clin Cancer Res 14, 300-308, 2008. (Pubitemid 351378006)
15. Jung SK, Lee KW, and Byun S: Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo. Carcinogenesis 31, 911-917, 2010.
16. Zhang XH, Zou ZQ, and Xu CW: Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting the activity of the cyclin B/Cdc2 complex. Mol Med Report 4, 273-277, 2011.
17. Araujo JR, Gonçalves P, and Martel F: Chemopreventive effect of dietary polyphenols in colorectal cancer cell lines. Nutr Res 31, 77-87, 2011.
18. Luo J, Manning BD, and Cantley LC: Targeting the PI3K-Akt pathwayin human cancer: rationale and promise. Cancer Cell 4, 257-62, 2003. (Pubitemid 37329790)
19. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al.: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30, 193-204, 2004.
20. Cuadrado A and Nebreda AR: Mechanisms and functions of p38 MAPK signalling. Biochem J 429, 403-417, 2010.
21. Shahjee HM, Koch KR, and Guo L: Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res 29, 160, 2010.
22. Astuti P, Pike T, and Widberg C: MAPK pathway activation delays G2/M progression by destabilizing Cdc25B. J Biol Chem 284, 33781-33788, 2009.
23. KessenbrockK, PlaksV, andWerb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67, 2010.
24. Liu FT, Agrawal SG, and Movasaghi Z: Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 112, 3835-3846, 2008.
25. Gonçalves P, Araujo JR, and Pinho MJ: In vitro studies on the inhibition of colon cancer by butyrate and polyphenolic compounds. Nutr Cancer 63, 282-294, 2011.
26. Paganga G and Rice-Evans CA: The identification of flavonoids as glycosides in human plasm. FEBS Lett 401, 78-82, 1997. (Pubitemid 27051262)